Chest diseases Hospital Laboratory Hematology standard Practice guidelines

Size: px
Start display at page:

Download "Chest diseases Hospital Laboratory Hematology standard Practice guidelines"

Transcription

1 Chest diseases Hospital Laboratory Hematology standard Practice guidelines Title Clearance criteria for adult surgical procedures SOP Code Policy Owner Hematology Unit Section Hematology Prepared By Dr. Taher Ahmed Abdelhameed Issuing Date 3May2015 Reviewed by: Dr. Samah E. ElShinnawy First revision 3 May2017 Second revision 3May2019 Dr. Hanan Elwazan Dr. Ahlam Jeragh Dr Abdulla Dashty Dr Tareq Aleinati Dr Muhamed ElMutairi Dr Nader Alawdhi Clearance criteria for adult surgical procedures page1of9

2 1.0 Purpose: Ensure safe surgical or procedural outcome by performing preoperative hematology laboratory tests. Patients should be assessed by Hematologist if the laboratory tests show abnormalities that can affects the surgical outcome. 2.0 Policy statement(s): Evaluating the patient preoperatively is performed by the Surgeon/Anesthesiologist in charge. Hematologist play a role when the preoperative hematology laboratory tests shows abnormalities which can affect patient outcome. Hematologist should asses the patient by history taking, clinical examination and further testing according to the results of the preoperative tests. In emergency situation, where the patient requires urgent procedures, Hematologist can be contacted by phone if required. 3.0 Responsibility: All CDH Hematologists can use this practice guidelines. Consultant/ Head of unit should assure that Physicians comply with guidelines. Approve any changes or updates to this guidelines. Lab Director ensures compliance with this guidelines. 4.0 Restrictions: 5.0 Principle: This guidelines is to be used only by hematologists of CDH. To ensure that the patient has been properly assessed by hematologist prior to surgery/procedure. Assessment should include personal or family history of hematologic diseases, thrombosis or bleeding. Physical examination should include general status of the patient & systemic review according to the patient complaint &/or abnormal laboratory result. Clearance criteria for adult surgical procedures page2of 9

3 6.0 Definitions: CBC : Complete blood count DAT: Direct Antiglobulin Test IAT: Indirect Antiglobulin Test RFT: Renal function Tests LFT : Liver Function Tests TFT : Thyroid function Tests PT: Prothrombin Time aptt: activated Partial Thromboplastin Time ANC : Absolute Neutrophil Count 7.0:Procedure: Preoperative hematology tests should include CBC with differential count,pt, aptt, blood grouping, Rh typing,antibody screening, sickling test & G6PD screening test. History taking : With special emphasis on current, past bleeding, thrombosis, anemia,drug intake,history of transfusion of blood/blood products, history of previous operations. Family history of bleeding or thrombotic problems 8.0 : Physical examination : ü Position in bed, conscious state, vital signs (Temp, BP, HR, RR) ü mouth & gum, skin,eye, mucous membrane colour, any evidence of bleeding, ü Examination of liver & spleen. ü examination of lymph nodes ( submental, cervical, axillary, inguinal & epitrochlear) if there is splenomegaly ü Examination of lower limbs for oedema, skin & colour changes, swelling, varicosities. 9.0 Assessment of anemia: ü Preoperative anemia should be properly diagnosed & managed in relation to the degree of urgency of the operation. ü Anemia diagnosis and management is mainly based on classification according to RBCs indices and morphology on peripheral smear examination into : Microcytic hypochromic anemia which is mainly either iron deficiency anemia or Thalassemia. Normocytic normochromic anaemia which is mostly either hemorrhagic, hemolytic or secondary to chronic disease,rarely due to double deficiency. Macrocytic anemia mostly secondary to hypoproliferative marrow whether primary or secondry to vitaminb12 &/or Folate deficiency. Clearance criteria for adult surgical procedures page3of 9

4 The following algorithm is to be used : Preoperative anemia management Urgent operation Elective operation Permissible HB HB 8-10gm/dl Type of anemia Threshold>/=10g/dl PRBCs Transfusion According to MCV,MCH MCV,MCH N MCV,MCH MCV Iron profile,serum ferritin & HB electrophoresis Smear Retics B12 Folate Smear Retics Thalassemia trait Iron deficiency DAT IAT RFT Iron supplements When HB >10 gm/dl Patient can be operated upon TFT Collagen screen LFT Clearance criteria for adult surgical procedures page4of 9

5 ü Preoperative sickling test & G6PD are usually requested by the surgeon in the last OPD visit, Positive tests should be confirmed by a further confirmatory & quantitative test. ü Partial exchange transfusion is advised in sickle cell anemia to reduce HB S to < 30 % & keep HB >10 gm/dl. ü Avoiding drugs that deteriorates the condition is clearly documented, with requesting substitute. 10.0: Assessment of thrombocytopenia: Minimun platelet count can be accepted as a permissible ceiteria differs according to the procedure needed as follows in table 1 : Table1: permissive platelet count in relation to the procedure Procedure name Cardiac surgery Coronary angio/pci Central line placement Endoscopy ( without biopsy) Endoscopy ( biopsy) Lumber puncture Gastroscopy (biopsy) Epidural anesthesia Liver biopsy Neurosurgery Ocular Surgery Permissive platelet count /Ul ( practice) /Ul /Ul /Ul /UL If the surgery/ procedure is elective, patient has to be referred to OPD for further diagnosis& treatment. If the surgery is urgent patients can be sent to OR ( considering that the other screening coagulation parameters are normal) after ensuring adequate platelet stock for probable transfusion. All thrombocytopenic patients,who had previous exposure to unfractionated heparin or Clexane HIT should be ruled out by clinical assessment ( 4T score ) or HIT serology. Special consideration is also given to postoperative drugs needed like postoperative antiplatelet drugs needed. Clearance criteria for adult surgical procedures page5of 9

6 11.0: Assessment of erthrocytosis: Patients with a raised venous haematocrit (Hct) (>52 % in males, >48% females) are referred to hematology. The recommendation will be : proper hydration, D/C diuretics ( after cardiologist/nephro approval). If still not corrected : venesection is advised to reach a target of 45%. The volume removed should be commensurate with the patient s size and comorbidities. Venesection is done by the ward nurse under supervision of the treating physician. Patients with a congenital cyanotic heart disease, develop secondary polycythemia to their cyanosis, the haematocrit may reach levels greater than 65% and symptoms of hyperviscosity usually develop at higher cutoff. Venesection is usually advised on bases of symptoms together with the hematocrit level. 12.0: Assessment of Neutropenia/neutrophelia: Cases of neutropenia ( ANC < 500/UL) to diagnose the cause of neutropenia & advices to cover the procedure by antibiotic if a benign chronic cause is suspected after reviewing the peripheral smear. Cases of leucocytosis ( WBCs >30.000/UL ) after smear review, if a hematologic malignancy is suspected, patient is to be referred to KCC and cleared from his hematologic oncologist. 13. Assessment coagulation condition: Ideally, INR & aptt ratio are to be within the range of 1:0 to 1.3(each).In urgent conditions if INR is >1.4 & aptt >40 seconds, FFp transfusion in the dose of 15 ml /kg is given 4 hours before surgery & reassess pt/inr & aptt just before surgery. In more elective condition, the prolongation of the clotting time should be investigated, cause defined & treated. Clearance criteria for adult surgical procedures page6of 9

7 14.0:Clearance for urgent procedures : There are many bedsideprocedures done during the patient stay in CDH, some of them need hematologic clearance. The decision varies when the patient is on anticoagulant/antiplatelet drugs, where he has to be evaluated bearing in the benefits & and risks of stopping/continuing the drug as follows :( considering the risk of the procedure is the bleeding risk, while the risk of the condition is the thrombotic risk that necessitates the anticoagulant/antiplatelet therapy) 1. Low risk procedure in a patient with high or low risk condition : a) Warfarin is kept, INR is kept therapeutic ( less than 3) b) Full dose antiplatelet therapy( Plavix) to be continued. 2. High risk procedures, low risk conditions ( bridging unnecessary): a) Warfarin to be stopped 5 days before the procedure ( INR should be less than 1.5) b) Warfarin to be restarted on the evening of the procedure in the usual daily dose. c) Plavix to be stopped 7 days before the procedure. d) Aspirin to be continued if already prescribed. If the patient was not on aspirin, aspirin can cover the period of plavix discontinuation. 3. High risk procedure,high risk condition ( bridging required) a) Warfarin to be stopped 5 days before the procedure. b) Bridging with LMWH (therapeutic dose ) to be started 2 days after discontinuing warfarin. Omit LMWH on the day of the procedure. c) Warfarin is to be restarted on the night of the procedure in the same dose. LMWH is to be continued till INR is therapeutic. d) Plavix is to be discontinued 7 days befor the procedure ( after cardiologist approval, if 12 months post DES placement/ or one month of BMS placement). Plavix is to be restarted the day after the procedure. Low risk procedures ( bleeding risk less than 1%) Central Venous line placement, IVC filter,tooth extraction, upper & lower GI endoscopy ( with biopsy),swan ganz catheter, arterial line, IABP, peritoneal aspiration,pericardiocentesis,tracheostomy,coronary angiography Ø Warfarin is kept with a target INR of 2.5. Ø Full-dose antiplatelet therapy (e.g., Plavix) to be continued through these procedures. High risk procedures ( bleeding risk more than 1%) Cardiac catherterization,pci, cardiac ablation,pacemaker placement, Transbronchial biopsy, arterial puncture, Lumber puncture, Ø low individual risk for thrombosis, anticoagulation can be interrupted without bridging therapy (heparin). Ø Most patients at high individual risk of thrombosis should receive bridging anticoagulation therapy. Clearance criteria for adult surgical procedures page 7 of9

8 Bridging therapy is strongly recommended for people with: DVT or PE within the past 3 months or severe thrombophilia. Mechanical mitral valves. "Old" design mechanical aortic valves (caged-ball or tilting-disk design, i.e., nonbileaflet). Any mechanical valve with a history of stroke or transient ischemic attack, Non-valvular atrial fibrillation with a CHADS2 score 4 or greater. history of stroke or TIA, or cardiac thrombus. Low risk condition ( for thrombosis) 1.Metal valave in the Aortic position. 2.Tissue heart valve. 3. AF without valve disease 4.DVT after first 3 months of therapy 5.thromboembolism 1.Warfarin to be stopped 5 days before the procedure, INR should reach 1.5 before the procedure 2.Warfarin to be restarted within 24 hours High risk condition 1.Metal valve in the mitral position. 2.AF and any type of prothetic valve 3.AF with Mitral stenosis. 4.AF withvalvular heart disease ( surgically corrected or not) 5.AF with any of: thromboembolic disease, LVF ( EF less than 35%) hypercoagulable disease, DM, HTN, age more than 75 years 6.Recently Placed Coronary stent ( less than 1 year) 7. Acute Coronary Syndrome. 8. Mechanical valve with H/O thromboembolic disease. 9.Recent conversion of AF 10. First 3 months of treating DVT/PE 11. thrombophelic syndrome 1, Warfarin to be stopped 5 days before the procedure. 2. When INR less than 2, LMWH to be started 3. LMWH to be omitted4-6 hours before the procedure. 4. LMWH to be restarted after the procedure. 5.Warfarin to be started at the evening of the procedure. 3.LMWH to be continued till warfarin is therapeutic. Clearance criteria for adult surgical procedures page8of 9

9 15.0procedural notes: Having a whole overview of the patient condition, and being responsible for the surgery, the surgeons and anesthetist sometimes are willing to increase or decrease some cutoffs for the clearance for certain surgeries or certain patients due to overlapping other conditions or diseases, which pushes us to try to correct a certain parameter in the laboratory data either by transfusion or therapy, though it coincides with this SOP. 16.0: References: 1. Transfusion guidelines : when to transfuse : 2013 ; Szczepiorkowski &Dunbar, Transfusion Medicine ( ASH Guidelines) 2. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients : 2013 : Retter et al.,british Journal of Hematology,160, Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis:2005: British Journal of Haematology, 130, UpToDate 2014: Clinical & laboratory aspects of platelet transfusion therapy: 5. Red Blood cell transfusion : A Clinical Practice guidelines from AABB : 2012: Carson et al., Annals of Internal Medicine,49-58 (American College of Physicians). 6. Recommendation for the transfusion of red cells :2009: Liumbruno etal., Blood Transfus :7: Evidence based Platelet Transfusion :2007, Slichter, Transfusion Medicine : Australian Medical Association guidelines on Patient examination Revised The ACCP 9th edition clinical practice guidelines for prevention and treatment of venous thromboembolism,perioperative management of antithrombotic therapy 2012 Clearance criteria for adult surgical procedures page9of9

10

Chest diseases Hospital Hematology Patient care plans

Chest diseases Hospital Hematology Patient care plans Chest diseases Hospital Hematology Patient care plans Hematology Service in CDH in a consultation service for management of hematologic complications of cardiology/ cardiac surgery. Primary hematologic

More information

Chest diseases Hospital Laboratory Hematology Practice guidelines

Chest diseases Hospital Laboratory Hematology Practice guidelines Chest diseases Hospital Laboratory Hematology Practice guidelines Title RBCs transfusion in Adults SOP Code Policy Owner Hematology Unit Section Hematology Prepared By Dr. Taher Ahmed Abdelhameed Issuing

More information

Hematologic Disorders. Assistant professor of anesthesia

Hematologic Disorders. Assistant professor of anesthesia Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's

More information

Oral anti-thrombotic therapy-management in patients requiring endoscopy

Oral anti-thrombotic therapy-management in patients requiring endoscopy Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients

More information

WARFARIN: PERI-OPERATIVE MANAGEMENT

WARFARIN: PERI-OPERATIVE MANAGEMENT WARFARIN: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin-treated patients who require an elective or urgent surgery/procedure. To provide an approach

More information

WARFARIN: PERI OPERATIVE MANAGEMENT

WARFARIN: PERI OPERATIVE MANAGEMENT WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach

More information

Clinical Practice Guideline for Anticoagulation Management

Clinical Practice Guideline for Anticoagulation Management Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.

More information

Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures

Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures This is an official Northern Trust policy and should not be edited in any way Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures Reference Number: NHSCT/11/454

More information

Clinical Practice Committee Anticoagulation Bridging Document

Clinical Practice Committee Anticoagulation Bridging Document Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure

More information

4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients

4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients 4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients Assess Thrombosis risk: baseline risk in an individual patient plus additional thrombotic risk

More information

Prostate Biopsy Alerts

Prostate Biopsy Alerts Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table

More information

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get

More information

ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı

ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı Dr. Sabri DEMİRCAN Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kardiyoloji ABD, Samsun Copyright 2001 Harcourt Canada Ltd.

More information

Slide 1: Perioperative Management of Anticoagulation

Slide 1: Perioperative Management of Anticoagulation Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY

More information

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or

More information

Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins

Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines

More information

Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi

Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K B. Cosmi Department of Angiology and Blood Coagulation S. Orsola-Malpighi University Hospital Bologna, Italy Overview Background

More information

Perioperative Management of the Anticoagulated Patient

Perioperative Management of the Anticoagulated Patient Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center

More information

Dental Management Considerations for Patients on Antithrombotic Therapy

Dental Management Considerations for Patients on Antithrombotic Therapy Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine

More information

CASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation

CASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation

More information

Challenges in Anticoagulation and Thromboembolism

Challenges in Anticoagulation and Thromboembolism Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

Asif Serajian DO FACC FSCAI

Asif Serajian DO FACC FSCAI Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac

More information

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran. Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct

More information

Preoperative Management of Patients Receiving Antithrombotics

Preoperative Management of Patients Receiving Antithrombotics Preoperative Management of Patients Receiving Antithrombotics Bleeding complications remain an important concern for most surgical procedures. Attempts to minimize the risk of these complications by removing

More information

Guidelines for Anticoagulation in Paediatric Cardiac Patients

Guidelines for Anticoagulation in Paediatric Cardiac Patients Leeds Children s Hospital Guidelines for Anticoagulation in Paediatric Cardiac Patients SURGICAL PATIENTS Preoperative Management Blalock-Taussig (BT) Shunt / Fontan circulation / Sano Shunt and Severe

More information

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17 2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical

More information

t. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines.

t. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines. Name or Policy: Policy Number: 3364-133-116 Department: Approving Officer: Responsible Agent: cope: x Management of Anticoagulation with Invasive Procedures Pharmacy Chief Operating Officer Director of

More information

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical

More information

Anticoagulation Transitions: Perioperative Care

Anticoagulation Transitions: Perioperative Care Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical Associates Four Questions for each Consultation 1.

More information

EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY

EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY K.A.O. Tikkinen (Chair), R. Cartwright, M.K. Gould, R. Naspro, G. Novara, P.M. Sandset, P.D. Violette, G.H. Guyatt Introduction Utilising recent

More information

HEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS

HEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS 1 of 6 Policy #: 800 (PLH-800-13) Initiated Date: 12/4/2002 Reviewed Date: 8/1/2016 Subject: HEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS Approved by: Laboratory Director, Jerry Barker (electronic signature)

More information

Managing Perioperative Anticoagulation. Edie Shen MD

Managing Perioperative Anticoagulation. Edie Shen MD Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)

More information

Pathology Service User Guide Haematology

Pathology Service User Guide Haematology Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin

More information

PCCN Review Hematology

PCCN Review Hematology PCCN Review Hematology Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC CEN, CNRN, CMSRN, NP Education Specialist LRM Consulting Nashville, TN Anemia Definition reduction in RBC concentration Causes iron deficiency

More information

Bridging anticoagulation definition

Bridging anticoagulation definition Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic

More information

Haematology dilemma s to refer or not to refer?

Haematology dilemma s to refer or not to refer? Haematology dilemma s to refer or not to refer? NWL Pathology GP Study Day Dr Fatts Chowdhury Consultant Haematologist in Transfusion Medicine NHS Blood and Transplant Senior Honorary Clinical Lecturer

More information

Perioperative Management of Anticoagulation

Perioperative Management of Anticoagulation Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:

More information

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients

More information

2.5 Other Hematology Consult:

2.5 Other Hematology Consult: The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR

More information

Low-Molecular-Weight Heparin

Low-Molecular-Weight Heparin Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:

More information

What You Should Know

What You Should Know 1 New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know The American Society

More information

Heparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital

Heparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital Heparin-Induced Thrombocytopenia Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital Heparin-induced thrombocytopenia (HIT) A serious concern associated with thrombosis development following

More information

Perioperative Anticoagulation Management

Perioperative Anticoagulation Management Perioperative Anticoagulation Management ACP Delaware Chapter Scientific Meeting Feb 9, 2019 Andrew Dunn, MD, MPH, MACP Chief, Division of Hospital Medicine Mount Sinai Health System, NY DISCLOSURES Desai

More information

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy: Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division

More information

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the

More information

Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355)

Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355) Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355) This document supports

More information

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)

More information

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer

More information

MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR

MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma

More information

Nursing Process Focus: Patients Receiving Heparin

Nursing Process Focus: Patients Receiving Heparin Obtain complete heath history including allergies, drug history and possible drug Assess baseline coagulation studies and CBC. Assess for history of bleeding disorders, GI bleeding, cerebral bleed, recent

More information

Peri-Procedural Management of Antithrombotic Agents

Peri-Procedural Management of Antithrombotic Agents u Peri-Procedural Management of Antithrombotic Agents An Integrated Care Pathway of the Collaborative Care Network Subject Matter Experts: Will Maxted, MD Veronica Kerner, PharmD Pathway Custodian: Pat

More information

Perioperative management of Anticoagulant and Antiplatelet medication GL067

Perioperative management of Anticoagulant and Antiplatelet medication GL067 Perioperative management of Anticoagulant and Antiplatelet medication GL067 Approval Approval Group Job Title, Chair of Committee Date Anaesthetics Clinical Governance Chair, Anaesthetics Clinical November

More information

Low-Molecular-Weight Heparin

Low-Molecular-Weight Heparin Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2016 Section: Prescription Drugs

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients

More information

Periprocedural Anticoagulation Adult Inpatient and Ambulatory Clinical Practice Guideline

Periprocedural Anticoagulation Adult Inpatient and Ambulatory Clinical Practice Guideline Periprocedural Anticoagulation Adult Inpatient and Ambulatory Clinical Practice Guideline A. Scope (disease/condition, treatment, clinical specialty) 1. Adult patients undergoing a procedure or surgery

More information

The Management of Patients on Chronic Oral Anticoagulant Therapy (VKA and DOAC) who Need Elective Surgery. Alex C. Spyropoulos MD, FACP, FCCP, FRCPC

The Management of Patients on Chronic Oral Anticoagulant Therapy (VKA and DOAC) who Need Elective Surgery. Alex C. Spyropoulos MD, FACP, FCCP, FRCPC The Management of Patients on Chronic Oral Anticoagulant Therapy (VKA and DOAC) who Need Elective Surgery Alex C. Spyropoulos MD, FACP, FCCP, FRCPC Professor of Medicine Hofstra Northwell School of Medicine

More information

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,

More information

To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin

To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin Omprakash Pansara, MD Brian Kline, MD St. Joseph s Health Family Medicine Residency Program, Syracuse, NY Case 75yr old male, who

More information

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic? Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer

More information

NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT

NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide guidance for the peri-operative management of patients who are receiving a newer direct oral anticoagulant (DOAC) and require an elective surgery/procedure.

More information

NOACS/DOACS*: COAGULATION TESTS

NOACS/DOACS*: COAGULATION TESTS NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international

More information

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address

More information

Primary Care practice clinics within the Edmonton Southside Primary Care Network.

Primary Care practice clinics within the Edmonton Southside Primary Care Network. INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized

More information

Venous Thromboembolism National Hospital Inpatient Quality Measures

Venous Thromboembolism National Hospital Inpatient Quality Measures Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation

More information

Part 1 examination. Haematology: First paper. Tuesday 20 March Candidates must answer all questions. Each question is worth a total of 25 marks.

Part 1 examination. Haematology: First paper. Tuesday 20 March Candidates must answer all questions. Each question is worth a total of 25 marks. Part 1 examination Haematology: First paper Tuesday 20 March 2018 Candidates must answer all questions. Each question is worth a total of 25 marks. Time allowed: 3 hours Question 1: General Haematology

More information

Blood Transfusion Guidelines in Clinical Practice

Blood Transfusion Guidelines in Clinical Practice Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi

More information

Diagnosis & Management of Heparin-Induced Thrombocytopenia

Diagnosis & Management of Heparin-Induced Thrombocytopenia Diagnosis & Management of Heparin-Induced Thrombocytopenia An Educational Slide Set American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism Slide set authors: Eric Tseng

More information

Clinical Controversies in Perioperative Medicine

Clinical Controversies in Perioperative Medicine Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Predicting & Managing Cardiac Risk A 70-y.o. man with progressive

More information

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)

More information

Do s and Don t of DOACs DISCLOSURE

Do s and Don t of DOACs DISCLOSURE Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier

More information

Challenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest

Challenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest Challenges in Anticoagulation Bridging and Emerging Therapies Ethan Cumbler MD FACP Associate Professor of Medicine Hospitalist Medicine Section University of Colorado Denver 2011 Disclosures and Relationships

More information

Approach to a pale child

Approach to a pale child Approach to a pale child Dr. Dafalla Ahmed Babiker Jazan university objectives Definition of anemia Classification and causes Important points in history and physical examination Investigations. Definition

More information

Taking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss

Taking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss Taking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss Joanne Eddington, MN, FNP, AOCN Providence Oncology and Hematology Care Clinic - Eastside Blood Cell Abnormalities Abnormalities

More information

New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)

New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated

More information

on Anti-coagulants -- Is It Safe? And When to Stop?

on Anti-coagulants -- Is It Safe? And When to Stop? Endoscopy for Your Patient on Anti-coagulants -- Is It Safe? And When to Stop? John R. Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical

More information

Interpreting the CBC. Robert Miller PA Assistant Professor of Clinical Pediatrics and Family Medicine USC Keck School of Medicine Retired

Interpreting the CBC. Robert Miller PA Assistant Professor of Clinical Pediatrics and Family Medicine USC Keck School of Medicine Retired Interpreting the CBC Robert Miller PA Assistant Professor of Clinical Pediatrics and Family Medicine USC Keck School of Medicine Retired The CBC 3 Cell Lines RBCs WBCs Platelets Assess general health Make

More information

Endoscopy and the Anticoagulated Patient

Endoscopy and the Anticoagulated Patient Endoscopy and the Anticoagulated Patient John R. Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Objectives To accurately assess the risk

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor

More information

Hematology: Challenging Cases with Your Participation COPYRIGHT

Hematology: Challenging Cases with Your Participation COPYRIGHT Hematology: Challenging Cases with Your Participation Reed E. Drews, MD Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Question 1 Question 1 64-year-old man is evaluated during

More information

Anemia 1: Fourth year Medical Students/ October/21/ 2015/ Abdallah Abbadi.MD.FRCP Professor

Anemia 1: Fourth year Medical Students/ October/21/ 2015/ Abdallah Abbadi.MD.FRCP Professor Anemia 1: Fourth year Medical Students/ October/21/ 2015/ Abdallah Abbadi.MD.FRCP Professor Email: abdalla.awidi@gmail.com Main Hematological diseases A- Benign Hematology 1- Anemias 2- Bleeding disorders

More information

WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT

WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)

More information

Lahey Clinic Internal Medicine Residency Program: Curriculum for Hematology

Lahey Clinic Internal Medicine Residency Program: Curriculum for Hematology Lahey Clinic Internal Medicine Residency Program: Curriculum for Hematology Faculty representative: Neil Weiner, MD Resident representative: Guiherme Rabinowits, MD Revision date: February 28, 2006 Goals

More information

UNUSUAL PRESENTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS

UNUSUAL PRESENTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS UNUSUAL PRESENTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS Presenter- Dr. Meghana B S Prof Dr. NAGARAJA B S Prof Dr. NIRMALA A C Dr. SIVARANJANI H Dr. B C PRAKASH Dr. MUMTAZ ALI KHAN A 60 year old lady, k/c/o

More information

Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy

Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy Curriculum in Cardiology Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy Syed M. Jafri, MD, FACC Detroit, Mich Patients receiving chronic anticoagulation therapy

More information

DVT - initial management NSCCG

DVT - initial management NSCCG Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis

More information

Xarelto rivaroxaban Prescriber Guide

Xarelto rivaroxaban Prescriber Guide Xarelto rivaroxaban Prescriber Guide Patient Alert Card A patient alert card must be provided to each patient who is prescribed Xarelto 2.5 mg, 10 mg, 15 mg or 20 mg and is provided with the product package.

More information

Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS

Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with

More information

Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354)

Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354) Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354) This document supports the

More information

Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders

Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is

More information

Laboratory Empowerment. Debbie Asher Adrian Ebbs Transfusion Laboratory Managers, Eastern Pathology Alliance

Laboratory Empowerment. Debbie Asher Adrian Ebbs Transfusion Laboratory Managers, Eastern Pathology Alliance Laboratory Empowerment Debbie Asher Adrian Ebbs Transfusion Laboratory Managers, Eastern Pathology Alliance Why? Electronic ICE requesting was in use for requesting red cells NBTC Indication Codes were

More information

Challenges in Coagulation

Challenges in Coagulation Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from

More information

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions

More information

Venous Thromboembolism Prophylaxis

Venous Thromboembolism Prophylaxis Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January

More information

Financial Disclosure. Objectives 9/24/2018

Financial Disclosure. Objectives 9/24/2018 Hemorrhage and Transfusion Adjuncts in the Setting of Damage Control Joseph Cuschieri, MD FACS Professor of Surgery, University of Washington Adjunct Professor of Orthopedics and Neurosurgery, University

More information

Evaluation of Anemia. Md. Shafiqul Bari Associate professor (Medicine) SOMC

Evaluation of Anemia. Md. Shafiqul Bari Associate professor (Medicine) SOMC Evaluation of Anemia Md. Shafiqul Bari Associate professor (Medicine) SOMC Definition Anemia is operationally defined as a reduction in one or more of the major RBC measurements Hemoglobin concentration

More information

An Audit of the Post-Operative Management of Patients taking Warfarin

An Audit of the Post-Operative Management of Patients taking Warfarin An Audit of the Post-Operative Management of Patients taking Warfarin Helen Wrightson Pre-Registration Pharmacist, Salisbury District Hospital March 2014 An Audit of the Post-Operative Management of Patients

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic

More information

HEFT Pathology Guideline. GP Investigation and Referral Pathways for leucocyte, platelet disturbances and polycythaemia

HEFT Pathology Guideline. GP Investigation and Referral Pathways for leucocyte, platelet disturbances and polycythaemia HEFT Pathology Guideline GP Investigation and Referral Pathways for leucocyte, platelet disturbances and polycythaemia Produced by: Dr Charalampos Kartsios (Consultant Haematologist) and Muhammad Javed

More information

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic

More information